Piramal Enterprises Limited Announces Consolidated Results for Q2 & H1 FY2021
– Resilient Performance despite a Challenging Business Environment Globally
– Net profit increased by 14% YoY to INR 628 Cr for Q2 FY21 and by 12% YoY to INR 1,124 Cr for H1 FY21
– Strengthened Balance Sheet and improved Liquidity position:
- Raised Long-Term Borrowings of ~INR 11,500 Cr. during H1 FY2021
- Received Growth Capital of INR 3,523.40 Cr. from The Carlyle Group in Piramal Pharma
Mumbai, India | October 28, 2020: Piramal Enterprises Limited (‘PEL’, NSE: PEL, BSE: 500302, 912460) today announced its consolidated results for the Second Quarter (Q2) and Half Year (H1) ended September 30, 2020.
|Consolidated Financial Highlights|
| Balance Sheet:
– Shareholders’ Equity increased by 28% to INR 34,739 Cr.* since Mar 19
– 39% reduction in Net Debt by nearly INR 22,000 Cr.* since Mar 2019
– Net Debt-to-Equity of below 1x times* at entity-level
*Post Pharma deal closed in October 2020
Inflows / Borrowings:
– Total inflows of ~INR 42,800 Cr. since April 2019, through equity and borrowing transactions
· Raised long-term borrowings of ~INR 11,500 Cr. during H1 FY2021
– Reduction in CPs to INR 2,100 Cr. as of Sep 2020 from INR 18,017 Cr. as of Sep 2018
– Revenue for Q2 FY21 increased by 1% YoY to INR 3,302 Cr.
– Net Profit for Q2 FY21 increased by 14% YoY to INR 628 Cr.
– Net Profit for H1 FY21 grew by 12% YoY to INR 1,124 Cr.
Mr. Ajay Piramal, Chairman, Piramal Enterprises Ltd. said, “We have delivered a resilient performance with net profit of INR 1,124 Crore for H1 FY21, despite adverse global environment. Continuing to focus on strengthening our balance sheet, over the past year, we brought in INR 18,000 Cr of capital and reduced our net debt-to-equity ratio to below 1x.
In Financial Services, we saw early signs of recovery across the key sectors that we lend to. Progressing on the stated strategy of diversifying the loan book, we will be launching our multi-product retail lending platform in November 2020.
The Pharma Business recorded a healthy improvement in both revenue growth and profitability. It also completed the 20% growth investment by The Carlyle Group – which is an affirmation of the robustness of the business model and consistency in performance. Both businesses are now at an inflection point, where we see a good runway for strong performances in the mid to long-term.”
|Key Business Highlights|
| In line with our Strategy to diversify our book, launching the multi-product Retail Lending business in Nov-2020
Early trends indicate better performance of developer clients than assumed under stressed scenario for creating provisions
Continue to increase granularity of our wholesale loan book.
– Exposure to only one account at >15% of the net worth of Financial Services
Conservative provisions of INR 3,037 Cr. as of Sep 2020, equivalent to 237% of GNPAs and 5.9% of overall loan book
Capital Adequacy Ratio at 34% (vs. 22% as of March 2019)
| Closed fund raising deal with The Carlyle Group
– Deal values our Pharma business at an Enterprise Value of USD 2.7 – 3.1 Bn.
– Received INR 3523.40 Cr. as proceed from Pharma Fund raise.
Revenue of INR 1,441 Cr. (+9% YoY) with EBITDA margins of 23% for Q2FY2021
– CDMO Revenue up 20% YoY
– India Consumer Products up 25% YoY
– CDMO order book witnessing healthy growth
– India Consumer Products business launched 15 products and 38 SKUs during the year
– Complex Hospital Generics now seeing recovery
– Cleared 4 regulatory inspections
|Business-wise Revenue Performance (INR Crores or as stated)|
|Net Sales break-up||Quarter II ended||Half year ended|
|30/9/20||30/9/19||% Change||% Sales||30/9/20||30/9/19||% Change||% Sales|
|Complex Hospital Generics||438||477||-8%||13%||763||891||-14%||12%|
|India Consumer Products||140||112||25%||4%||244||222||10%||4%|
|Consolidated Financial Performance (INR Crores or as stated)|
|Particulars||Quarter II ended||Half year Ended|
|30-Sep-20||30-Sep-19||% Change||30-Sep-20||30-Sep-19||% Change|
|Non-operating other income||38||46||-18%||103||110||-7%|
|Other Operating Expenses||1,278||1,188||8%||2,369||2,363||0%|
|Expected Credit loss||24||-107||75||-152|
|Profit / (Loss) before tax & exceptional items||742||770||-4%||1,364||1,441||-5%|
|Exceptional items (Expenses)/Income||39||0||39||0|
|Current Tax and Deferred Tax||204||258||-21%||365||474||-23%|
|DTA and MAT Credit written off||0||0||0||0|
|Profit/(Loss) after tax (before MI & Prior Period items)||578||512||13%||1,039||968||7%|
|Share of Associates||50||96||-48%||85||169||-50%|
|Net Profit/(Loss) after Tax from continuing operations||628||608||3%||1,124||1,137||-1%|
|Profit / (Loss) from Discontinued operations||0||-57||0||-137|
|Net Profit after Tax||628||551||14%||1,124||1,000||12%|
Note: Figures in previous periods might have been regrouped or restated, wherever necessary to make them comparable to current period.
To download the results presentation and for further information on our financials, please visit our website: www.piramal.com